{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,15]],"date-time":"2026-06-15T20:30:55Z","timestamp":1781555455399,"version":"3.54.5"},"reference-count":45,"publisher":"BMJ","issue":"7","license":[{"start":{"date-parts":[[2024,7,11]],"date-time":"2024-07-11T00:00:00Z","timestamp":1720656000000},"content-version":"unspecified","delay-in-days":10,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004339","name":"Sanofi","doi-asserted-by":"publisher","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}],"id":[{"id":"10.13039\/100004339","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Open"],"accepted":{"date-parts":[[2024,6,4]]},"published-print":{"date-parts":[[2024,7]]},"abstract":"<jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To evaluate background incidence rates of 59 health outcomes of interest (HOI) in a diverse population, including important subpopulations, during the pre-COVID-19 era (1 January 2017\u201331 December 2019) and the COVID-19 era (1 March 2020\u201331 December 2020), before the introduction of COVID-19 vaccines.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Design<\/jats:title>\n                    <jats:p>Observational retrospective cohort study. Annual incidence rates and 95% confidence intervals (CIs) of HOIs were estimated for each population of interest, stratified by: age, sex, age and sex and seasonality.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Data source<\/jats:title>\n                    <jats:p>Optum\u2019s de-identified Clinformatics Data Mart Database (CDM).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Participants<\/jats:title>\n                    <jats:p>Individuals from the US general population and four subgroups of interest: influenza-vaccinated, paediatric (&lt;18 years of age), elderly (\u226565 years of age) and pregnant women.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>During the COVID-19 era, the incidence of several cardiac conditions, coagulation disorders and acute liver injury increased across all populations assessed while the rates of some dermatological and neurological HOIs decreased relative to the pre-COVID-19 era. The incidence of acute respiratory distress syndrome (ARDS) varied considerably by subgroup: among the elderly, it decreased annually during the pre-COVID-19 era but peaked during the COVID-19 era; among pregnant women, it slightly increased annually during the pre-COVID-19 era and substantially increased during the COVID-19 era; among paediatrics, it decreased annually over the entire study. The incidence of the majority of HOIs increased with age, but were generally comparable between sexes with few exceptions. Cardiac, gastrointestinal, neurological and haematological HOIs, along with acute kidney injury and ARDS, were more common in males, whereas several immunological HOIs and chilblain-like lesions were more common in females. Pregnancy-related HOIs did not increase during the COVID-19 era, except for spontaneous abortions which increased annually over the entire study.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>These observations help contextualise fluctuations in background rates of adverse events noted during the COVID-19 era, and provide insight on how their use may impact safety surveillance for other vaccines.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/bmjopen-2024-083947","type":"journal-article","created":{"date-parts":[[2024,7,11]],"date-time":"2024-07-11T20:05:43Z","timestamp":1720728343000},"page":"e083947","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":2,"title":["Background incidence rates of health outcomes of interest for COVID-19 vaccine safety monitoring in a US population: a claims database analysis"],"prefix":"10.1136","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3581-9318","authenticated-orcid":false,"given":"Sonja","family":"Banga","sequence":"first","affiliation":[{"name":"Sanofi, Toronto, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alena","family":"Khromava","sequence":"additional","affiliation":[{"name":"Sanofi, Toronto, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurence","family":"Serradell","sequence":"additional","affiliation":[{"name":"Sanofi, Lyon, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne-Laure","family":"Chabanon","sequence":"additional","affiliation":[{"name":"Sanofi, Lyon, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chunshen","family":"Pan","sequence":"additional","affiliation":[{"name":"Sanofi, Bridgewater, New Jersey, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irisdaly","family":"Estevez","sequence":"additional","affiliation":[{"name":"Aetion Inc, New York, New York, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samantha","family":"Schilsky","sequence":"additional","affiliation":[{"name":"Aetion Inc, New York, New York, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hannah","family":"Kreisberg","sequence":"additional","affiliation":[{"name":"Aetion Inc, New York, New York, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2024,7,11]]},"reference":[{"key":"2025120519504351000_14.7.e083947.1","unstructured":"World Health Organization . WHO Coronavirus (COVID-19) Dashboard, 2023. Available: https:\/\/covid19.who.int"},{"key":"2025120519504351000_14.7.e083947.2","doi-asserted-by":"crossref","first-page":"2712","DOI":"10.1016\/j.vaccine.2021.03.016","article-title":"The critical role of background rates of possible adverse events in the assessment of COVID-19 vaccine safety","volume":"39","author":"Black","year":"2021","journal-title":"Vaccine"},{"key":"2025120519504351000_14.7.e083947.3","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1016\/j.vaccine.2022.11.003","article-title":"Background rates of adverse events of special interest for COVID-19 vaccine safety monitoring in the United States, 2019-2020","volume":"41","author":"Moll","year":"2023","journal-title":"Vaccine"},{"key":"2025120519504351000_14.7.e083947.4","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.n1435","article-title":"Characterising the background incidence rates of adverse events of special interest for COVID-19 vaccines in eight countries: multinational network cohort study","volume":"373","author":"Li","year":"2021","journal-title":"BMJ"},{"key":"2025120519504351000_14.7.e083947.5","doi-asserted-by":"publisher","DOI":"10.1007\/s40264-014-0204-5"},{"key":"2025120519504351000_14.7.e083947.6","unstructured":"EMA . Guideline on good pharmacovigilance practices (GVP), 2013. Available: https:\/\/www.ema.europa.eu\/en\/documents\/scientific-guideline\/guideline-good-pharmacovigilance-practices-gvp-product-population-specific-considerations-i-vaccines_en.pdf"},{"key":"2025120519504351000_14.7.e083947.7","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1002\/pds.3918","article-title":"Pharmacoepidemiological considerations in observed-to-expected analyses for vaccines","volume":"25","author":"Mahaux","year":"2016","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"2025120519504351000_14.7.e083947.8","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2022.11.031"},{"key":"2025120519504351000_14.7.e083947.9","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2023.101932","article-title":"Contextualising adverse events of special interest to Characterise the baseline incidence rates in 24 million patients with COVID-19 across 26 databases: a multinational retrospective cohort study","volume":"58","author":"Voss","year":"2023","journal-title":"EClinicalMedicine"},{"key":"2025120519504351000_14.7.e083947.10","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1007\/s10067-022-06478-4","article-title":"Real-world patient characteristics and use of disease-modifying anti-rheumatic drugs in patients with rheumatoid arthritis: a cross-national study","volume":"42","author":"Ingrasciotta","year":"2023","journal-title":"Clin Rheumatol"},{"key":"2025120519504351000_14.7.e083947.11","doi-asserted-by":"crossref","unstructured":"Indiana University Bloomington . Optum Clinformatics data Mart. 2023. Available: https:\/\/ssrc.indiana.edu\/data\/optum.html","DOI":"10.2979\/13126.0"},{"key":"2025120519504351000_14.7.e083947.12","unstructured":"Optum . Clinformatics data Mart (CDM). 2017. Available: https:\/\/www.optum.com\/content\/dam\/optum\/resources\/productSheets\/Clinformatics_for_Data_Mart.pdf"},{"key":"2025120519504351000_14.7.e083947.13","doi-asserted-by":"crossref","first-page":"2824","DOI":"10.1016\/j.vaccine.2012.02.057","article-title":"Health outcomes of interest for evaluation in the post-Licensure rapid immunization safety monitoring program","volume":"30","author":"Lieu","year":"2012","journal-title":"Vaccine"},{"key":"2025120519504351000_14.7.e083947.14","first-page":"1","article-title":"Validating Notifications of pregnancy Terminations for birth defects before 20 weeks gestation","volume":"30","author":"Riley","year":"2002","journal-title":"Health Inf Manag"},{"key":"2025120519504351000_14.7.e083947.15","doi-asserted-by":"crossref","DOI":"10.3346\/jkms.2020.35.e35","article-title":"Epidemiology of Antiphospholipid syndrome in Korea: a nationwide population-based study","volume":"35","author":"Hwang","year":"2020","journal-title":"J Korean Med Sci"},{"key":"2025120519504351000_14.7.e083947.16","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2022.814198","article-title":"Factors influencing background incidence rate calculation: systematic empirical evaluation across an international network of observational databases","volume":"13","author":"Ostropolets","year":"2022","journal-title":"Front Pharmacol"},{"key":"2025120519504351000_14.7.e083947.17","unstructured":"Kawai AT . Mini-sentinel\/CBER protocol vaccines administered in pregnancy and birth outcomes: A project to develop data infrastructure and design framework, 2017. Available: https:\/\/sentinelinitiative.org\/sites\/default\/files\/vaccines-blood-biologics\/assessments\/Influenza-Vaccines-and-Birth-Outcomes-Revised-Protocol.pdf"},{"key":"2025120519504351000_14.7.e083947.18","unstructured":"FDA-Sentinel . COVID-19 History Master Protocol, 2021. Available: https:\/\/www.sentinelinitiative.org\/sites\/default\/files\/Methods\/COVID-19-Natural_History_Protocol_v3.0.pdf"},{"key":"2025120519504351000_14.7.e083947.19","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2021.05.016"},{"key":"2025120519504351000_14.7.e083947.20","doi-asserted-by":"publisher","DOI":"10.1111\/j.1572-0241.2007.01456.x"},{"key":"2025120519504351000_14.7.e083947.21","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1080\/13696998.2021.1922262","article-title":"Burden of illness among Medicare and non-Medicare US populations with acquired thrombotic Thrombocytopenic purpura","volume":"24","author":"Pollissard","year":"2021","journal-title":"J Med Econ"},{"key":"2025120519504351000_14.7.e083947.22","article-title":"Preparing for the ICD-10-CM transition: automated methods for translating ICD codes in clinical phenotype definitions","volume":"4","author":"Fung","year":"2016","journal-title":"EGEMS (Wash DC)"},{"key":"2025120519504351000_14.7.e083947.23","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1002\/pds.2312","article-title":"A systematic review of validated methods for identifying cerebrovascular accident or transient ischemic attack using administrative data","volume":"21 Suppl 1","author":"Andrade","year":"2012","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"2025120519504351000_14.7.e083947.24","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.21037\/jtd-20-3062","article-title":"Coagulation disorders and thromboembolic disease in COVID-19: review of current evidence in search of a better approach","volume":"13","author":"Garc\u00eda-Ortega","year":"2021","journal-title":"J Thorac Dis"},{"key":"2025120519504351000_14.7.e083947.25","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1001\/jama.2022.15801","article-title":"Seasonal variability of disease","volume":"329","year":"2023","journal-title":"JAMA"},{"key":"2025120519504351000_14.7.e083947.26","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccc.2021.05.001"},{"key":"2025120519504351000_14.7.e083947.27","doi-asserted-by":"crossref","first-page":"1875","DOI":"10.4254\/wjh.v14.i10.1875","article-title":"Alcohol use disorder and liver injury related to the COVID-19 pandemic","volume":"14","author":"Marano","year":"2022","journal-title":"World J Hepatol"},{"key":"2025120519504351000_14.7.e083947.28","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1002\/hep.31404","article-title":"Acute liver injury in COVID-19: prevalence and association with clinical outcomes in a large U.S","volume":"72","author":"Phipps","year":"2020","journal-title":"Hepatology"},{"key":"2025120519504351000_14.7.e083947.29","doi-asserted-by":"crossref","DOI":"10.1186\/s43066-022-00230-y","article-title":"COVID-19-associated liver injury, role of drug therapy and management: a review","volume":"12","author":"Iheanacho","year":"2022","journal-title":"Egypt Liver J"},{"key":"2025120519504351000_14.7.e083947.30","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2020.24984","article-title":"Changes in health services use among commercially insured US populations during the COVID-19 pandemic","volume":"3","author":"Whaley","year":"2020","journal-title":"JAMA Netw Open"},{"key":"2025120519504351000_14.7.e083947.31","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2020-045343","article-title":"Impact of COVID-19 pandemic on utilisation of Healthcare services: a systematic review","volume":"11","author":"Moynihan","year":"2021","journal-title":"BMJ Open"},{"key":"2025120519504351000_14.7.e083947.32","first-page":"185","article-title":"Vaccines against influenza: WHO position paper \u2013 may 2022","volume":"97","year":"2022","journal-title":"Wkly Epidemiol Rec"},{"key":"2025120519504351000_14.7.e083947.33","doi-asserted-by":"crossref","DOI":"10.1016\/j.arr.2020.101124","article-title":"Effects of influenza vaccination on the risk of cardiovascular and respiratory diseases and all-cause mortality","volume":"62","author":"Cheng","year":"2020","journal-title":"Ageing Res Rev"},{"key":"2025120519504351000_14.7.e083947.34","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1007\/s11886-023-01875-w","article-title":"Correlation between cardiovascular protection and influenza vaccination","volume":"25","author":"Ngwudike","year":"2023","journal-title":"Curr Cardiol Rep"},{"key":"2025120519504351000_14.7.e083947.35","article-title":"Influenza vaccines for preventing cardiovascular disease","volume":"2015","author":"Clar","year":"2015","journal-title":"Cochrane Database Syst Rev"},{"key":"2025120519504351000_14.7.e083947.36","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/cix524"},{"key":"2025120519504351000_14.7.e083947.37","doi-asserted-by":"crossref","unstructured":"Kopsaftis Z , Wood-Baker R , Poole P . n.d. Influenza vaccine for chronic obstructive pulmonary disease (COPD). Cochrane Database Syst Rev 2018:CD002733. doi:10.1002\/14651858.CD002733.pub3","DOI":"10.1002\/14651858.CD002733.pub3"},{"key":"2025120519504351000_14.7.e083947.38","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/j.ijid.2020.02.040","article-title":"Who and when to vaccinate against influenza","volume":"93","author":"Buchy","year":"2020","journal-title":"Int J Infect Dis"},{"key":"2025120519504351000_14.7.e083947.39","unstructured":"National Vital Statistics System . Vital Statistics rapid release. 2021. Available: https:\/\/www.cdc.gov\/nchs\/data\/vsrr\/vsrr012-508.pdf"},{"key":"2025120519504351000_14.7.e083947.40","unstructured":"United States Census Bureau . Age and Sex Composition in the United States, 2018. Available: https:\/\/www.census.gov\/data\/tables\/2018\/demo\/age-and-sex\/2018-age-sex-composition.html"},{"key":"2025120519504351000_14.7.e083947.41","unstructured":"United States Census Bureau . Age and Sex Composition in the United States, 2017. Available: https:\/\/www.census.gov\/data\/tables\/2017\/demo\/age-and-sex\/2017-age-sex-composition.html"},{"key":"2025120519504351000_14.7.e083947.42","unstructured":"United States Census Bureau . Age and Sex Composition in the United States, 2019. Available: https:\/\/www.census.gov\/data\/tables\/2019\/demo\/age-and-sex\/2019-age-sex-composition.html"},{"key":"2025120519504351000_14.7.e083947.43","unstructured":"United States Census Bureau . Age and Sex Compositon in the United States, 2020. Available: https:\/\/www.census.gov\/data\/tables\/2020\/demo\/age-and-sex\/2020-age-sex-composition.html"},{"key":"2025120519504351000_14.7.e083947.44","doi-asserted-by":"crossref","first-page":"2101","DOI":"10.1186\/s12889-023-16999-5","article-title":"Differential care-seeking behaviors during the beginning of the covid-19 pandemic in michigan: a population-based cross-sectional study","volume":"23","author":"Vander Woude","year":"2023","journal-title":"BMC Public Health"},{"key":"2025120519504351000_14.7.e083947.45","doi-asserted-by":"crossref","first-page":"552","DOI":"10.15585\/mmwr.mm7015a3","article-title":"Update: COVID-19 pandemic-associated changes in emergency Department visits - United States","volume":"70","author":"Adjemian","year":"2020","journal-title":"MMWR Morb Mortal Wkly Rep"}],"container-title":["BMJ Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjopen-2024-083947","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,6]],"date-time":"2025-12-06T03:50:58Z","timestamp":1764993058000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmjopen.bmj.com\/lookup\/doi\/10.1136\/bmjopen-2024-083947"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7]]},"references-count":45,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2024,7,11]]},"published-print":{"date-parts":[[2024,7]]}},"alternative-id":["10.1136\/bmjopen-2024-083947"],"URL":"https:\/\/doi.org\/10.1136\/bmjopen-2024-083947","relation":{},"ISSN":["2044-6055","2044-6055"],"issn-type":[{"value":"2044-6055","type":"print"},{"value":"2044-6055","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,7]]}}}